CLDN5 and neoplasm: Cldn5 downregulation is a common feature in several tumor types, such as breast invasive carcinoma, cervical cancer, and lung adenocarcinomas and squamous cell carcinomas, where it contributes to the compromise of the blood–tumor barrier, thereby facilitating vascular leakage, tumor cell infiltration, and metastasis [42].